Clinical Trial Update: Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial investigating pegylated interferon to reduce relapse after stopping nucleos(t)ide therapy in chronic hepatitis B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)

Snippet

Sponsor: Huashan Hospital | Conditions: Chronic Hepatitis B | Phase 4 | Status: COMPLETED